


STEREOSPECIFIC SYNTHESIS OF LEUKOTRIENE B₄ (LTB₄)

By Yvan Guindon*, Robert Zamboni, Cheuk-Kun Lau and Joshua Rokach
 Merck Frosst Laboratories, P.O. Box 1005,
 Pointe-Claire/Dorval, Québec, Canada H9R 4P8


Summary: A stereospecific and chirally economical synthesis of LTB₄ starting from 2-deoxy-D-ribose is reported as part of a comprehensive and efficient approach to the Leukotrienes (A, B, C, D, E). The process includes a novel approach to chiral dienic synthons.

Leukotriene B₄ (1) is a component of the arachidonic acid cascade which has been recently isolated¹ and characterized². This local hormone stimulates leukocyte functions³ (chemotaxis, chemokinesis), induces an increase in capillary permeability³ and causes smooth muscle contraction⁴. The potential importance of LTB₄ in allergic and inflammatory states and the need for a better supply to investigate its properties prompted us to embark on the synthesis of this mediator which we are now reporting.



Our approach is based on the realization that the common synthetic precursor, 2-deoxy-D-ribose (2), which has been used in the stereospecific synthesis^{5,6} of LTA₄, 5-epi-LTA₄, 6-epi-LTA₄ and 5-epi,6-epi-LTA₄ could also be utilized in the preparation of LTB₄. In particular, we recognized the potential stereochemical and functional overlap between the hydroxyls at C-5 and C-12 of LTB₄ (1) and those at C-3 and C-4 of 2, respectively.


The key step in our synthesis is based on our finding that some C-glycosides which possess a leaving group on the tetrahydrofuran ring, could be considered as masked dienic precursors, as illustrated in the stereospecific conversion of 3 to 4. (The structure of 4 was secured by sodium periodate oxidation to yield ethyl (E, E)-6-oxo-2,4-hexadienoate and comparison with authentic material⁷). The formation of compound 4 can be explained by a β-elimination to give the corresponding α,β-unsaturated ester derivative 5 which rearranges under the basic conditions to 4.



Based on this observation, it was envisaged that replacement of the primary hydroxyl group in the C-glycoside 3 with an alkyl side chain (e.g. compound 6) and subsequent treatment with base will give the corresponding chiral diene alcohol (7) bearing the desired R configuration. The condensation of this C-14 fragment with the C-6 piece, 19, would give LTB₄, 1, stereospecifically.

The preparation of the key intermediates 7 and 19 was carried out as follows. Reaction of 2 with 1.2 equivalent of (carbethoxymethylene)triphenylphosphorane in refluxing THF for 6 hours gave the triol 8 in 80% yield^{5,6}. The C-glycoside (α/β :1/1) 9 were then obtained by treating 8 with a catalytic amount of sodium ethoxide in ethanol (95% yield).


Selective tosylation of the primary alcohol 9 (1.1 equivalent TsCl, pyr.) and subsequent treatment with 2 equivalents of *tert*-butyldimethylsilyl chloride (CH₂Cl₂, Et₃N, DMAP) gave the derivative 10 (82%). Displacement of the tosylate with sodium iodide in refluxing acetone (18 hours) led to the 7-iodo-C-glycoside 11 in 70% yield. The chain extension was then realized by adding the iodide 11 (at -25°) to the heterocuprate reagent 12⁸ (in ether), in the presence of 0.3 equivalent excess of CuBr·Me₂S⁹, to obtain, after 16 hours, the C-14 unit 13 (36% isolated yield with 25% recovered starting material)¹⁰.




Removal of the silyl group (nBu₄NF, THF) and subsequent mesylation (MsCl, Et₃N, CH₂Cl₂) of the resulting alcohol gave the key intermediates 6 in 71% yield. Treatment of 6 with 2.5 equivalents of sodium ethoxide in ethanol (0.5 hours, R.T.) led cleanly to the dienic synthon 7 in 90% yield, $[\alpha]_D^{25} = +11.4^\circ$ (c 1.31, CDCl₃) which was transformed into 14 (90% yield), $[\alpha]_D^{25} = +44.8^\circ$ (c 1.25, CDCl₃) using *tert*-butyldiphenylsilylchloride¹¹ (Et₃N, CH₂Cl₂). The ester 14 was then reduced by AlH₃ (THF) to the alcohol 15, $[\alpha]_D^{25} = +21.9^\circ$ (c 1.67, CDCl₃). Bromination of the primary alcohol (CBr₄, 2.5 equiv., Ph₃P, 2 equiv., 0°) and its displacement with Ph₃P (5 equiv.) in acetonitrile (R.T., 1.5 hrs) provided the C-7 to C-20 segment, in the form of the Wittig reagent 16.

Since the stereochemistry at C-3 of the starting sugar, 2, was identical to that at C-5 of LTB₄, the synthesis of the C-1 to C-6 segment of 1 was done using the same intermediates. Hydrogenation of the α,β -unsaturated ester 8 and formation of the kinetically favored acetonide,

as we previously reported⁵, gave the alcohol 17 in good yield. Benzoylation of 17 (BzCl, Et₃N, CH₂Cl₂, DMAP) and a subsequent treatment with 1N HCl in MeOH (2 hrs, 60°) gave in 50% yield the corresponding diol 18. The oxidative cleavage of the vicinal diol using 1.1 equiv. of lead tetraacetate in CH₂Cl₂ containing 2 equiv. of sodium carbonate² led to the aldehyde 19 in 65% yield [α]_D = -46° (c 0.5, CHCl₃) (lit.²: -33° for the corresponding methyl ester, CHCl₃).



The synthesis of LTB₄ was then completed as follows. The phosphonium salt, 16, in THF was treated with 1.1 equiv. of BuLi at -78° to which 1.3 equiv. of aldehyde 19 was added. The reaction was allowed to proceed at -40° for 15 min. Extractive isolation and purification by HPLC¹² gave the $\Delta^{6,7}$ cis compound 20 (30% yield from 15), [α]_D = +202° (c 1.2, CHCl₃) and $\Delta^{6,7}$ trans isomer 21¹³ (12% yield from 15), [α]_D = +106° (c 1.0, CHCl₃). The compound 22, [α]_D = +260° (c 1.0, CHCl₃)¹⁴, obtained in 80% yield from 20 (nBu₄NF, 10 equiv.) was then treated with K₂CO₃ (10 equiv.) in MeOH-H₂O (4:1) to give LTB₄¹⁵ (1) cleanly in 60% yield, U.V. (max.) CH₃OH·260, 270.5, 281.



The identity of the synthetic material with native LTB₄¹⁶ was assured by comparison of their HPLC behaviour¹⁷ and their biological activities¹⁸.

The present synthesis of LTB₄ can be considered as being chirally economical since all the chiral centers of the synthetic precursor are maintained as chiral centers in the final target molecule. As such, it constitutes part of our comprehensive approach to the Leukotrienes, since from the same precursor, 2-deoxy-D-ribose (2), one can also obtain optically active LTA₄, LTC₄, LTD₄ and LTE₄ and their respective isomers^{5,6}.

ACKNOWLEDGMENT:

The authors would like to extend their thanks to Dr. J. Atkinson for helpful discussions during the preparation of the manuscript.

REFERENCES

1. P. Borgeat and B. Samuelsson, *J. Biol. Chem.*, **254**, 2643 (1979).
2. Characterization and synthesis a) E.J. Corey, A. Marfat, G. Goto and F. Brion, *J. Am. Chem. Soc.*, **102**, 7984 (1980); b) E.J. Corey, A. Marfat, J. Monroe, K.S. Kim, P.B. Hopkins and F. Brion, *Tetrahedron Lett.*, **22**, 1077 (1981).
3. a) A.W. Ford-Hutchinson, M.A. Bray, M.V. Doing, M.E. Shipley and M.S.H. Smith, *Nature (London)*, **286**, 264 (1980); b) R.M.J. Palmer, R.J. Stepley, G.A. Higgs, and K.E. Eakins, *Prostaglandins*, **20**, 411 (1980), c) M.A. Bray, A.W. Ford-Hutchinson and M.J.H. Smith, *Br. J. Pharmac.*, **73**, 259 (1981), d) G.A. Higgs and K.E. Eakins, *Prostaglandins*, **20**, 411 (1980) and e) M.A. Bray, F.M. Cunningham, A.W. Ford-Hutchinson and M.J.H. Smith, *Br. J. Pharmac.*, **72**, 483 (1981).
4. a) P. Sirois, P. Borgeat, A. Jeanson, S. Roy and G. Girard, *Prostaglandins and Medicine*, **5**, 429 (1980), b) P. Sirois, J. Roy and P. Borgeat, *Prostaglandins and Medicine*, **6**, 153 (1981).
5. J. Rokach, R. Zamboni, C.K. Lau and Y. Guindon, *Tetrahedron Lett.*, **22**, 2759 (1981).
6. J. Rokach, C.K. Lau, R. Zamboni and Y. Guindon, *Tetrahedron Lett.*, **22**, 2763 (1981).
7. J. Rokach, Y. Girard, Y. Guindon, J.G. Atkinson, M. Larue, R.N. Young, P. Masson and G. Holme, *Tetrahedron Lett.*, **21**, 1485 (1980).
8. H.O. House and M. Umen, *J. Org. Chem.*, **38**, 3893 (1973).
9. The yield of the substitution product **14** relative to that of the elimination products was improved by the addition of excess $\text{CuBr} \cdot \text{Me}_2\text{S}$. Although the role of excess $\text{CuBr} \cdot \text{Me}_2\text{S}$ is not yet known, it is possible that the reactive species is no longer the stoichiometric $\text{RR}'\text{CuLi}$ but rather $\text{R}_3\text{R}_3'\text{Cu}_4\text{Li}_2$ which may be less basic hence decreases the yield of elimination compounds.
10. The cuprate reaction on both the α and β C-glycosides was investigated separately and each gave the corresponding substitution product **11** in comparable yields.
11. S. Hanessian, P. Lavallée, *Can. J. Chem.*, **53**, 2975 (1975).
12. Waters μ -Porasil column; 98.5% hexane/.5% EtOAc/1% Et₃N as solvent.
13. 400 MHz pmr: cis isomer, H_6 appeared as a quartet at $\delta 5.43$ ppm. $J_{5,6} = 7\text{Hz}$, $J_{6,7} = 11\text{Hz}$; trans isomer, H_6 appeared as a quartet at $\delta 5.65$ ppm. $J_{5,6} = 7\text{Hz}$, $J_{6,7} = 14.5\text{Hz}$.
14. The methyl ester analog of **22** has surprisingly a reported $[\alpha]_D$ of $+164^\circ$, see ref. 2.
15. pmr (400 MHz, CD_3SOCD_3 , of syn. LTB_4) $\delta 6.59$ (q, 1H, H_8 , $J_{8,9} = 14\text{Hz}$, $J_{7,8} = 12\text{Hz}$), 6.31 (m, 2H, $\text{H}_9 + \text{H}_{10}$), 6.02 (t, 1H, H_7 , $J_{6,7} = J_{7,8} = 11\text{Hz}$), 5.80 (q, 1H, H_{11} , $J_{11,12} = 6.5\text{Hz}$, $J_{10,11} = 14\text{Hz}$), 5.50 (m, 3H, H_{14} , H_{15} , OH), 5.48 (q, 1H, H_6 , $J_{6,7} = 11\text{Hz}$, $J_{5,6} = 7.0\text{Hz}$), 4.96 (m, 1H, OH), 4.46 (m, 1H, H_5), $\delta 4.10$ (m, 1H, H_{12}) ppm.
16. We would like to thank Dr. A.W. Ford-Hutchinson (King's College Hospital Medical School, London, England) and Dr. P. Borgeat (Centre Hospitalier Université Laval, Québec, Canada) for kindly supplying us with samples of natural LTB_4 for HPLC comparison.
17. Synthetic LTB_4 was identical to natural LTB_4 in two solvent system (40% CH_3CN / 60% H_2O / .01% AcOH, 65% MeOH / 35% H_2O / .01% AcOH; on a Waters C_{18} μ -bondapak column.
18. Biological activities comparisons were performed by Dr. A.W. Ford-Hutchinson and by Dr. M. Springer, Dr. P. Davies and Dr. A. Rosenthal, Merck & Co., Rahway, New Jersey.

(Received in USA 3 November 1981)